Synthetic biology technologies have ushered in remarkable advances in cellular engineering, growing our arsenal of tools for cancer treatment. Increasingly, the metabolic pathways of cells have emerged as attractive targets for rewiring cell behavior, enhancing the efficacy of such treatments as T cell-receptor (TCR)- and chimeric antigen receptor (CAR)-based immunotherapies. In this Cell Press Webinar, Shikhar Mehrotra (Medical University of South Carolina), Greg Delgoffe (University of Pittsburgh), and Jeff Rathmell (Vanderbilt University Medical Center), and Nicholas Restifo (National...
